Seasonal Influenza Vaccines – Japan Drug Forecast and Market Analysis to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza. The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Japan from 2015-2025.

Analysis of the impact of key events as well the drivers and restraints affecting Japan Seasonal Influenza Vaccines market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2015-2025 in Japan.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Symptoms and Prognosis

4Disease Management

4.1Seasonal Influenza Immunization Policy

4.1.1Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

4.2Japan

4.2.1Influenza Immunization Recommendations and Policies

4.2.2Clinical Practice

5Competitive Assessment

5.1Overview

5.2Product Profiles – Major Brands, Inactivated Vaccines

5.2.1Fluzone Quadrivalent

5.2.2Fluzone High-Dose

5.2.3Fluzone Intradermal

5.2.4Vaxigrip

5.2.5Fluarix Tetra

5.2.6Fluvirin

5.2.7Afluria

5.2.8Agrippal

5.3Product Profiles – Major Brands, Inactivated Vaccines (Adjuvanted)

5.3.1Fluad

5.4Product Profiles – Major Brands, Live-Attenuated Vaccines

5.4.1FluMist Quadrivalent

5.5Product Profiles – Major Brands, Cell Cultured Vaccines

5.5.1Flublok

5.5.2Flucelvax

5.6Other Seasonal Influenza Vaccines

5.6.1Influvac

5.6.2Minor Brands

6Unmet Needs and Opportunity Analysis

6.1Overview

6.2Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

6.2.1Unmet Need

6.2.2Gap Analysis

6.2.3Opportunity

6.3Immunization Policies Targeting Children and Adolescents

6.3.1Unmet Need

6.3.2Gap Analysis

6.3.3Opportunity

6.4Enhanced Vaccine Efficacy in High-Risk Groups

6.4.1Unmet Need

6.4.2Gap Analysis

6.4.3Opportunity

6.5Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

6.5.1Unmet Need

6.5.2Gap Analysis

6.5.3Opportunity

6.6Improving the Cost-Effectiveness of Influenza Vaccines

6.6.1Unmet Need

6.6.2Gap Analysis

6.6.3Opportunity

6.7Vaccines with Broader Influenza Strain Coverage

6.7.1Unmet Need

6.7.2Gap Analysis

6.7.3Opportunity

6.8Improved Vaccine Safety Profile

6.8.1Unmet Need

6.8.2Gap Analysis

6.8.3Opportunity

7Pipeline Assessment

7.1Overview

7.2Promising Vaccines in Clinical Development

7.2.1Seasonal Influenza VLP Vaccine

7.2.2VN-100

7.2.3Quadrivalent Seasonal Influenza VLP Vaccine

7.3Promising Vaccines in Early-Stage Development

7.3.1FLU-v

7.3.2M-001

7.3.3TAK-850

7.3.4VAX-2012Q

7.4Other Vaccines in Development Outside the 7MM

8Market Outlook

8.1Japan

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Vaccine Coverage

9.4.2Vaccines Included

9.4.3Key Launch Dates

9.4.4Influenza Vaccine Tender System Assumptions

9.4.5General Pricing Assumptions

9.4.6Individual Vaccine Assumptions

9.4.7Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for this Report

9.6Primary Research – Prescriber Survey

9.7About the Authors

9.7.1Analyst

9.7.2Therapy Area Director

9.7.3Epidemiologists

9.7.4Director of Epidemiology

9.7.5Global Director of Therapy Analysis and Epidemiology

9.8About GlobalData

9.9Disclaimer

Table

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 5: Country Profile –Japan

Table 6: Leading Seasonal Influenza Vaccines, 2016

Table 7: Product Profile – Fluzone Quadrivalent

Table 8: Immunogenicity Profile of Fluzone Quadrivalent

Table 9: Local and Systemic AEs of Fluzone Quadrivalent

Table 10: Fluzone Quadrivalent SWOT Analysis, 2016

Table 11: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025

Table 12: Product Profile – Fluzone High-Dose

Table 13: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 14: Local and Systemic AEs of Fluzone High-Dose

Table 15: Fluzone High-Dose SWOT Analysis, 2016

Table 16: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025

Table 17: Product Profile – Fluzone Intradermal

Table 18: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 19: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 20: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 21: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025

Table 22: Product Profile – Vaxigrip

Table 23: Cumulative Incidence of Influenza Infection in Children

Table 24: Local and Systemic AEs of Vaxigrip

Table 25: Vaxigrip SWOT Analysis, 2016

Table 26: Global Sales Forecast ($m) for Vaxigrip, 2015–2025

Table 27: Product Profile – Fluarix Tetra

Table 28: Immunogenicity Profile of Fluarix Tetra

Table 29: Local and Systemic AEs of Fluarix Tetra

Table 30: Fluarix Tetra SWOT Analysis, 2016

Table 31: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025

Table 32: Product Profile – Fluvirin

Table 33: Immunogenicity of Fluvirin in Adults

Table 34: Local and Systemic AEs of Fluvirin

Table 35: Fluvirin SWOT Analysis, 2016

Table 36: Global Sales Forecast ($m) for Fluvirin, 2015–2025

Table 37: Product Profile – Afluria

Table 38: Immunogenicity of Afluria in Adults

Table 39: Local and Systemic AEs of Afluria

Table 40: Afluria SWOT Analysis, 2016

Table 41: Global Sales Forecast ($m) for Afluria, 2015–2025

Table 42: Product Profile – Agrippal

Table 43: Immunogenicity of Agrippal

Table 44: Local and Systemic AEs of Agrippal

Table 45: Agrippal SWOT Analysis, 2016

Table 46: Global Sales Forecast ($m) for Agrippal, 2015–2025

Table 47: Product Profile – Fluad

Table 48: Immunogenicity Comparison of Fluad Versus Agriflu

Table 49: Local and Systemic AEs of Fluad

Table 50: Fluad SWOT Analysis, 2016

Table 51: Global Sales Forecast ($m) for Fluad, 2015–2025

Table 52: Product Profile – FluMist Quadrivalent

Table 53: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 54: AEs of FluMist Quadrivalent

Table 55: FluMist Quadrivalent SWOT Analysis, 2016

Table 56: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025

Table 57: Product Profile – Flublok

Table 58: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 59: Local and Systemic AEs of Flublok

Table 60: Flublok SWOT Analysis, 2016

Table 61: Global Sales Forecast ($m) for Flublok, 2015–2025

Table 62: Product Profile – Flucelvax

Table 63: Immunogenicity of Flucelvax

Table 64: Local and Systemic AEs of Flucelvax

Table 65:Flucelvax SWOT Analysis, 2016

Table 66: Global Sales Forecast ($m) for Flucelvax, 2015–2025

Table 67: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 68: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 69: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016

Table 70: Quadrivalent Versions of Marketed Vaccines

Table 71: Product Profile – Seasonal Influenza VLP Vaccine

Table 72: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 73: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025

Table 74: Product Profile – VN-100

Table 75: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 76: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 77: VN-100 SWOT Analysis, 2016

Table 78: Global Sales Forecast ($m) for VN-100, 2015–2025

Table 79: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine

Table 80: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 81: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025

Table 82: Promising Vaccines in Early-Stage Development, 2016

Table 83: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 84: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015–2025

Table 85: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025

Table 86: Japan Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 87: Key Launch Dates

Table 88: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Influenza Virus Structure

Figure 2: Seasonal Influenza Vaccines – Phase II/Phase III Pipeline, 2016

Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015–2025

Figure 4: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025

Frequently asked questions

Seasonal Influenza Vaccines – Japan Drug Forecast and Market Analysis to 2025 thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Seasonal Influenza Vaccines – Japan Drug Forecast and Market Analysis to 2025 in real time.

  • Access a live Seasonal Influenza Vaccines – Japan Drug Forecast and Market Analysis to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.